{"id":727007,"date":"2023-01-31T06:03:32","date_gmt":"2023-01-31T11:03:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\/"},"modified":"2023-01-31T06:03:32","modified_gmt":"2023-01-31T11:03:32","slug":"reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\/","title":{"rendered":"Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference"},"content":{"rendered":"
\n

Cupertino, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the BIO CEO and Investor Conference being held February 6\u20139, 2023 in New York, NY. Please see additional details below:<\/p>\n

\n 2023 BIO CEO and Investor Conference<\/strong>\n <\/p>\n\n\n\n\n\n
Date:<\/td>\n\u00a0<\/td>\nMonday, February 6, 2023<\/td>\n<\/tr>\n
Time:<\/td>\n\u00a0<\/td>\n11:30 p.m. EST<\/td>\n<\/tr>\n
Speaker:<\/td>\n\u00a0<\/td>\nLaxminarayan Bhat, Founder & CEO of Reviva Pharmaceuticals<\/em><\/td>\n<\/tr>\n
Format:<\/td>\n\u00a0<\/td>\nCompany Presentation<\/td>\n<\/tr>\n<\/table>\n

For information about the BIO CEO and Investor Conference, please refer to the events website<\/a>.<\/p>\n

\n About Reviva
<\/strong>Reviva\u00a0is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva\u2019s current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva\u2019s pipeline currently includes two drug candidates,\u00a0RP5063\u00a0(brilaroxazine) and\u00a0RP1208. Both are new chemical entities discovered in-house.\u00a0Reviva\u00a0has been granted composition of matter patents for both\u00a0RP5063\u00a0and R1208 in\u00a0the United States\u00a0(U.S.),\u00a0Europe, and several other countries.<\/p>\n

\n Forward-Looking Statements
<\/strong>This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to the Company\u2019s product development, clinical and regulatory timelines and expenses, market opportunity, ability to raise sufficient funding, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management\u2019s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpotential, \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201cwould\u201d and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company\u2019s filings with the\u00a0Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.<\/p>\n

\n Corporate Contact:<\/strong>
\n
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com<\/a><\/p>\n

\n Investor Relations Contact:<\/strong>
\n
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Cupertino, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the BIO CEO and Investor Conference being held February 6\u20139, 2023 in New York, NY. Please see additional details below: 2023 BIO CEO and Investor Conference Date: \u00a0 Monday, February 6, 2023 Time: \u00a0 11:30 p.m. EST Speaker: \u00a0 Laxminarayan Bhat, Founder & CEO of Reviva Pharmaceuticals Format: \u00a0 Company Presentation For information about the BIO CEO and Investor Conference, please … <\/p>\n

Continue reading “Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-727007","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nReviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Cupertino, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the BIO CEO and Investor Conference being held February 6\u20139, 2023 in New York, NY. Please see additional details below: 2023 BIO CEO and Investor Conference Date: \u00a0 Monday, February 6, 2023 Time: \u00a0 11:30 p.m. EST Speaker: \u00a0 Laxminarayan Bhat, Founder & CEO of Reviva Pharmaceuticals Format: \u00a0 Company Presentation For information about the BIO CEO and Investor Conference, please … Continue reading "Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-31T11:03:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczOTMzNCM1MzgyMjU3IzUwMDA3NTM4MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference\",\"datePublished\":\"2023-01-31T11:03:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\\\/\"},\"wordCount\":491,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczOTMzNCM1MzgyMjU3IzUwMDA3NTM4MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\\\/\",\"name\":\"Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczOTMzNCM1MzgyMjU3IzUwMDA3NTM4MQ==\",\"datePublished\":\"2023-01-31T11:03:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczOTMzNCM1MzgyMjU3IzUwMDA3NTM4MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczOTMzNCM1MzgyMjU3IzUwMDA3NTM4MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference - Market Newsdesk","og_description":"Cupertino, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (\u201cReviva\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the BIO CEO and Investor Conference being held February 6\u20139, 2023 in New York, NY. Please see additional details below: 2023 BIO CEO and Investor Conference Date: \u00a0 Monday, February 6, 2023 Time: \u00a0 11:30 p.m. EST Speaker: \u00a0 Laxminarayan Bhat, Founder & CEO of Reviva Pharmaceuticals Format: \u00a0 Company Presentation For information about the BIO CEO and Investor Conference, please … Continue reading \"Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-01-31T11:03:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczOTMzNCM1MzgyMjU3IzUwMDA3NTM4MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference","datePublished":"2023-01-31T11:03:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\/"},"wordCount":491,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczOTMzNCM1MzgyMjU3IzUwMDA3NTM4MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\/","name":"Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczOTMzNCM1MzgyMjU3IzUwMDA3NTM4MQ==","datePublished":"2023-01-31T11:03:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczOTMzNCM1MzgyMjU3IzUwMDA3NTM4MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczOTMzNCM1MzgyMjU3IzUwMDA3NTM4MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reviva-pharmaceuticals-to-present-at-the-2023-bio-ceo-and-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/727007","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=727007"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/727007\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=727007"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=727007"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=727007"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}